Clinical trials: Nervous System Disorders
Transient Insomnia
A Study of Single-Dose Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
The purpose of this study is to assess the effect of gabapentin as compared to placebo on sleep, using subjective sleep measurements, in subjects with transient insomnia induced by a sleep phase advance.
- Trial name
- NCT00667108
- Testing
- Gabapentin
- Where
- 8 sites in United States
- Volunteers
- 784 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Cerebral Stroke
FitMi Plus Home Therapy for Stroke Patients
The investigators will investigate the efficacy of a newly developed functional exercise device (FitMi Plus) for people in the chronic stage after a stroke compared to the FitMi Basic (i.e. without functional exercises).
- Trial name
- NCT03935425
- Testing
- FitMi Plus, FitMi Basic
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Flint Rehabilitation Devices, LLC
Progressive Multiple Sclerosis
A First-in-human, Single Ascending Dose Study of GZ402668 in Patients With Progressive Multiple Sclerosis
Primary Objective: To assess the safety and tolerability of GZ402668 after ascending single intravenous (IV) and subcutaneous (SC) doses in men and women with progressive multiple sclerosis.
- Trial name
- NCT02282826
- Testing
- GZ402668, acyclovir
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Genzyme, a Sanofi Company
Alzheimer's Disease
Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
This study will evaluate the safety and potential benefit of Dimebon as compared to placebo in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00377715
- Testing
- Dimebon
- Where
- Russia
- Volunteers
- 183 people
- Sponsor
- Medivation, Inc.
Age-Related Cognitive Decline, Age-Related Memory Disorders
Memory Improvement With Docosahexaenoic Acid Study (MIDAS)
The purpose of this study is to investigate the effect of docosahexaenoic acid (DHA, 22:6n-3) in improving cognitive functions in subjects with age-related cognitive decline.
- Trial name
- MIDAS (NCT00278135)
- Where
- 14 sites in United States
- Volunteers
- 485 people
- Sponsor
- dsm-firmenich Switzerland AG
Migraine Headache
A Study in Migraine Prevention
The primary objective of this study is to measure the change in frequency of migraine attacks per 28 days in migraine patients being treated orally with LY2300559 for 12 weeks.
- Trial name
- NCT01184508
- Testing
- LY2300559
- Where
- 12 sites in United States, Puerto Rico
- Volunteers
- 87 people
- Sponsor
- Eli Lilly and Company
Degenerative Disc Disease (DDD), Spinal Stenosis
PMCF Study on the Effectiveness and Safety of METROSAN Spinal Systems and BONEGRAFT Filling Materials
This is a prospective, multi-center, observational Post-Market Clinical Follow-Up (PMCF) study designed to collect additional safety and clinical performance data on CE-marked Titania® spinal instrumentation and fusion systems…
- Conditions
- Degenerative Disc Disease (DDD), Spinal Stenosis, Spondylolisthesis, Spinal Deformities
- Trial name
- INFO SPINE (NCT07615491)
- Testing
- Titania® Cervical Interbody Fusion Cage (Titanium), Titania® Cervical Interbody Fusion Cage (PEEK), Titania® Posterior Cervical Stabilization System
- Where
- 3 sites in Turkey (Türkiye)
- Volunteers
- 561 people
- Sponsor
- Metrosan End. ve Elk. Mek. Cihazlar ve Tibbi Malz. San. Tic. Ltd. Co.
Alzheimer Disease
A Phase 2 Study to Evaluate Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
- Trial name
- INVOKE-2 (NCT04592874)
- Testing
- AL002
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 356 people
- Sponsor
- Alector Inc.
Meniere's Disease, Ménière's Disease
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Study of the safety of open-label SPI-1005 400 mg BID treatment in adults with Meniere's Disease (MD) for 6 or 12 months to support chronic or chronic intermittent use.
- Trial name
- NCT06859788
- Testing
- Ebselen
- Where
- 9 sites in United States
- Volunteers
- 200 people
- Sponsor
- Sound Pharmaceuticals, Incorporated
Essential Tremor
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)
To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of…
- Trial name
- NCT04032470
- Testing
- Deep Brain Stimulation Systems (DBS)
- Where
- 20 sites in Austria, Belgium and 7 more
- Volunteers
- 500 people
- Sponsor
- Boston Scientific Corporation
Fabry Disease
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
This is a 12-month, parallel treatment, Phase 3, double-blind, randomized, placebo-controlled study to evaluate the effect of venglustat on neuropathic and abdominal pain symptoms of Fabry disease in participants ≥16 years of age…
- Trial name
- PERIDOT (NCT05206773)
- Testing
- Venglustat (GZ402671)
- Where
- 50 sites in United States, Argentina and 19 more
- Volunteers
- 122 people
- Sponsor
- Sanofi
Epilepsy; Paediatric Partial Onset Seizures
Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Study)
The purpose of this study is to compare the safety and efficacy of zonisamide with placebo.
- Trial name
- NCT00566254
- Testing
- Zonisamide
- Where
- 43 sites in Belgium, Estonia and 7 more
- Volunteers
- 207 people
- Sponsor
- Eisai Inc.
Multiple Sclerosis, Primary Progressive
A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis
This study will evaluate the efficacy and safety of ocrelizumab (Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants later in their disease course.
- Trial name
- O'HAND (NCT04035005)
- Testing
- Ocrelizumab
- Where
- 155 sites in United States, Australia and 21 more
- Volunteers
- 1,013 people
- Sponsor
- Hoffmann-La Roche
OSA
Continuation Protocol for Obstructive Sleep Apnea (OSA)
The combination drug composed of aroxybutynin and atomoxetine, designated AD109, is being developed by Apnimed for the treatment of obstructive sleep apnea (OSA).
- Trial name
- NCT06566820
- Testing
- Aroxybutynin and Atomoxetine
- Where
- 99 sites in United States, Canada
- Volunteers
- 1,280 people, healthy volunteers welcome
- Sponsor
- Apnimed
Fragile X Syndrome
Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)
This study is a multicenter, double-blind, randomized, placebo-controlled study to assess the safety and tolerability of 3 doses of MRM-3379 in male participants with Fragile X Syndrome ages 16 to 45 (inclusive).
- Trial name
- NCT07209462
- Testing
- Low dose of MRM-3379, Middle Dose of MRM-3379, High dose of MRM-3379
- Where
- 18 sites in United States, Spain
- Volunteers
- 60 people
- Sponsor
- Mirum Pharmaceuticals, Inc.
Gaucher Disease
Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
The primary purpose of this study is to evaluate the effect of VPRIV therapy (60 units per kilogram [U/kg] every other week [EOW]) in treatment-naive participants with type 1 Gaucher disease on change from baseline in lumbar…
- Trial name
- NCT02574286
- Testing
- Velaglucerase alfa, Vitamin D
- Where
- 15 sites in United States, Israel and 2 more
- Volunteers
- 21 people
- Sponsor
- Shire
Generalized Myasthenia Gravis
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab compared with placebo in participants with generalized myasthenia gravis (gMG).
- Trial name
- NCT04963270
- Testing
- Satralizumab
- Where
- 76 sites in United States, Argentina and 15 more
- Volunteers
- 188 people
- Sponsor
- Hoffmann-La Roche
Narcolepsy, Obstructive Sleep Apnea
The Nuvigil and Provigil Pregnancy Registry
The primary objective of the Nuvigil/Provigil Pregnancy Registry is to characterize the pregnancy and fetal outcomes associated with Nuvigil and Provigil exposure during pregnancy.
- Conditions
- Narcolepsy, Obstructive Sleep Apnea, Shift Work Sleep Disorder
- Trial name
- NCT01792583
- Testing
- Modafinil/armodafinil
- Where
- United States
- Volunteers
- 191 people, healthy volunteers welcome
- Sponsor
- Cephalon, Inc.
Glioblastoma Multiforme, Anaplastic Astrocytoma
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
In this study an investigational replication-defective, recombinant adenovirus expressing the interferon-beta gene (BG00001) will be directly injected into tumors, in patients with recurrent Grade III and Grade IV Gliomas, in…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligoastrocytoma, Mixed, Gliosarcoma
- Trial name
- NCT00031083
- Testing
- Interferon-beta
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Biogen
Optic Neuropathy, Ischemic
A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
The objective of this non-interventional study is to examine whether use of Phosphodiesterase Inhibitors (PDE5s), including use of sildenafil, vardenafil, or tadalafil, triggers the onset of acute NAION.
- Trial name
- NCT00759174
- Testing
- No intervention
- Where
- 105 sites in United States, France and 4 more
- Volunteers
- 673 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.